Table 5 Univariate logistic regression analysis for long-term pancreatic adverse outcomes
From: Clinical characteristics and outcomes of immune checkpoint inhibitor-induced pancreatic injury
Characteristic | Odds ratio (95% confidence interval) | P |
|---|---|---|
Age | 0.96 (0.92-1.02) | 0.234 |
Male | 2.60 (0.52-12.96) | 0.244 |
Smoking | 4.35 (1.06-17.81) | 0.041 |
Alcohol | 1.74 (0.48-6.24) | 0.397 |
Hyperlipidemia | 6.15 (1.24-30.55) | 0.026 |
Prior history of pancreatitis | 0.91 (0.10-8.24) | 0.936 |
Pancreatic metastasis | 0.61 (0.07-5.29) | 0.654 |
CTLA-4–based regimena | 1.54 (0.38-6.32) | 0.549 |
Continued immune checkpoint inhibitor therapy | 2.69 (0.72-10.04) | 0.141 |
Time from initiation of immune checkpoint inhibitors to onset | 0.99 (0.99-0.99) | 0.016 |
Pancreatic symptoms | 2.02 (0.40-10.13) | 0.393 |
Peak lipase value | 1.00 (0.99-1.01) | 0.274 |
Peak amylase value | 1.00 (0.99-1.01) | 0.404 |
Abnormal computed tomography findings | 0.49 (0.06-4.31) | 0.519 |
Intravenous fluids | 0.21 (0.06-0.79) | 0.022 |
Fluid resuscitation volume | 0.57 (0.16-1.99) | 0.380 |
Steroids | 1.44 (0.40-5.19) | 0.572 |
Hospitalization | 0.32 (0.04-2.66) | 0.291 |